激素受体IIA/IIB类型的阻断会增加肌肉质量和强度,但会影响小鼠的血糖控制
Michala Carlsson1, Emma Frank1, Joan M Màrmol2
1Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2200, Denmark.
Molecular metabolism
|September 29, 2025
概括
阻断Activin受体IIA/IIB类型 (ActRIIA/IIB) 增加肌肉质量和强度,但导致小鼠的葡萄糖不耐受和活动减少,与人类不同. 需要进一步的研究来了解这些特定物种的代谢效应.
科学领域:
- 肌肉生理学和代谢调节.
- 对代谢疾病的药理干预.
- 生物医学研究中的比较动物模型.
背景情况:
- 活性因子受体IIA和IIB类型 (ActRIIA/IIB) 的阻塞显示了增加肌肉质量和改善血糖控制的潜力.
- 对ActRIIA/IIB封锁对强度和代谢调节的影响尚未完全理解.
研究的目的:
- 研究短期和长期ActRIIA/IIB抗体治疗对肌肉质量,强度,新陈代谢调节和胰岛素作用在瘦和肥胖小鼠的影响.
- 为了比较ActRIIA/IIB封锁对小鼠的影响与人类研究.
主要方法:
- 在短时间 (40小时) 和长期 (21天) 期间,向瘦身和饮食诱导的肥胖小鼠注射ActRIIA/IIB抗体 (αActRIIA/IIB).
- 评估胰岛素刺激的葡萄糖吸收,血糖水平,耐葡萄糖,身体组成,肌肉力量和跑步能力.
- 使用工程人类肌肉组织来评估对Activin A.的反应.
主要成果:
- 短期治疗在瘦小鼠中增加了胰岛素刺激的葡萄糖吸收,但导致高血糖和葡萄糖不耐受.
- 肥胖小鼠的长期治疗增加了肌肉质量和力量,但引起了葡萄糖不耐受性,心脏缩和肝脏葡萄糖输出的增加.
- 尽管增加了肌肉质量和力量,但长期治疗减少了自愿跑步能力.
结论:
- ActRIIA/IIB阻塞增加肌肉质量,力量和肌肉胰岛素敏感性,与人类研究一致.
- 在小鼠中,ActRIIA/IIB阻塞矛盾地导致严重的葡萄糖不耐受和减少身体活动,与人类血糖控制的改善形成鲜明对比.
- 在血糖控制和ActRIIA/IIB封锁的代谢后果中存在显著的物种差异,需要进一步调查.
相关概念视频
Glucagon-like Receptor Agonists
848
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848
Dipeptidyl Peptidase 4 Inhibitors
594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594
Hormones Regulating Blood Glucose
6.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K


